Maxim Group Sticks to Its Buy Rating for Acurx Pharmaceuticals (ACXP)
Acurx Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Acurx Pharmaceuticals Amid Promising CDI Drug Candidate Progress and Solid Financials
H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating
Acurx Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $14 Price Target
Buy Rating for Acurx Pharmaceuticals Amid Promising Phase 2 Results and Positive Regulatory Momentum
Analysts' Top Healthcare Picks: Acurx Pharmaceuticals (ACXP), Champions Oncology (CSBR)
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH), Lisata Therapeutics (LSTA) and Acurx Pharmaceuticals (ACXP)
HC Wainwright & Co. Maintains Buy on Acurx Pharmaceuticals, Raises Price Target to $14
Acurx Pharmaceuticals Analyst Ratings
Promising Future for Acurx Pharmaceuticals: A Buy Rating Backed by Strong Financials, Successful Clinical Trials, and Strategic Market Positioning
Acurx Pharmaceuticals Analyst Ratings
Promising Trials and Undervaluation Make Acurx Pharmaceuticals a Buy: An Analysis of ACXP's Potential
Buy Rating on Acurx Pharmaceuticals: Promising Clinical Results and Financial Stability Highlighted by Analyst Ed Arce
Maxim Raises Price Target on Acurx Pharmaceuticals to $10 From $7, Keeps Buy Rating
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Acurx Pharmaceuticals (ACXP)
H.C. Wainwright Sticks to Its Buy Rating for Acurx Pharmaceuticals (ACXP)
Acurx Pharmaceuticals Analyst Ratings
Maxim Group Remains a Buy on Acurx Pharmaceuticals (ACXP)